Search Result

Results for "

LT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (3) Bacterial (1) c-Myc (2) CCR (1) CDK (2) COX (3) Dengue Virus (1) Epigenetic Reader Domain (1) Epoxide Hydrolase (2) FLAP (4) Flavivirus (1) FLT3 (4) HDAC (1) Histone Methyltransferase (1) Integrin (1) Interleukin Related (2) Isotope-Labeled Compounds (2) KLF (1) Leukotriene Receptor (5) Ligands for Target Protein for PROTAC (1) LPL Receptor (1) NF-κB (3) NO Synthase (2) P-selectin (1) Parasite (1) PARP (4) Phospholipase (1) PPAR (1) TNF Receptor (3)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (20) Metabolic Disease (4) Neurological Disease (1)

By Targets:

Androgen Receptor (1)

Apoptosis (3)

Bacterial (1)

c-Myc (2)

CCR (1)

CDK (2)

COX (3)

Dengue Virus (1)

Epigenetic Reader Domain (1)

Epoxide Hydrolase (2)

FLAP (4)

Flavivirus (1)

FLT3 (4)

HDAC (1)

Histone Methyltransferase (1)

Integrin (1)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

KLF (1)

Leukotriene Receptor (5)

Ligands for Target Protein for PROTAC (1)

LPL Receptor (1)

NF-κB (3)

NO Synthase (2)

P-selectin (1)

Parasite (1)

PARP (4)

Phospholipase (1)

PPAR (1)

TNF Receptor (3)

By Research Areas:

Cancer (15)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (20)

Metabolic Disease (4)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130622

LT052	Epigenetic Reader Domain	Inflammation/Immunology
LT052 is a highly selective BET BD1 inhibitor with an IC₅₀ of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC₅₀=12.130 μM). LT052 has anti-inflammatory?activity and can be used for acute gout arthritis research .

HY-121900

LT175	PPAR	Metabolic Disease Endocrinology
LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ(hPPARα:EC₅₀=0.22 μm; mPPARα:EC₅₀=0.26 μm; hPPARγ:EC₅₀=0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties .

HY-164768

LT25	Integrin	Cancer
LT25 (compound 17) is a agonist of α5β1 integrin with EC₅₀ value of 9.9 nM .

HY-P99318

Sonepcizumab LT 1009; Anti-Human S1P Recombinant Antibody	LPL Receptor	Cancer
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .

HY-123984

LTβR-IN-1	NF-κB	Metabolic Disease
LTβR-IN-1 is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1 regulates the NF-kB signaling pathway IN a ligand-independent manner .

HY-162378

LT-630	HDAC	Inflammation/Immunology
LT-630 is a HDAC6 inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage .

HY-155594

LT-540-717	FLT3	Cancer
LT-540-717 (compound 32) is a potent FLT3 inhibitor (IC₅₀=0.62 nM) with antiproliferative activity. LT-540-717 also inhibits several acquired FLT3 mutations, FLT3 (ITD, D835V), FLT3 (ITD, F691L), FLT3 (D835Y) and FLT3 (D835V). LT-540-717 has potential to be an anti-AML agent .

HY-139619

LT-850-166	FLT3	Cancer
LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations.

HY-163761

LT166	CCR	Others
LT166 is a fluorescent ligand for CC chemokine receptor 1 (CCR1) with a K_D of 1.90 μM .

HY-132828

Odatroltide LT3001; DHDMIQK(KAP)	P-selectin	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities .

HY-19675

Naproxen etemesil LT-NS 001; MX 1094	COX	Inflammation/Immunology
Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

HY-16106

Talazoparib Maximum Cited Publications 75 Publications Verification BMN-673; LT-673	PARP	Cancer
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-111361

FN-1501 1 Publications Verification LT-171-861	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

HY-16291

APTO-253 10+ Cited Publications LOR-253; LT-253	c-Myc KLF Apoptosis	Inflammation/Immunology Cancer
APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor . APTO-253 has antiarthritic activity .

HY-16291A

APTO-253 hydrochloride LOR-253 hydrochloride; LT-253 hydrochloride	c-Myc	Inflammation/Immunology
APTO-253?(LOR-253) hydrochloride is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253?hydrochloride mediates anticancer activity via induction of Kruppel-like factor 4?(KLF4)?tumor suppressor. APTO-253?hydrochloride exhibits antiarthritic activity .

HY-16106S1

Talazoparib-d4 BMN-673-d₄; LT-673-d₄	Isotope-Labeled Compounds PARP	Cancer
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-16106S

Talazoparib-13C,d4 BMN-673-¹³C,d₄; LT-673-¹³C,d₄	Isotope-Labeled Compounds	Others
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-151619

sEH inhibitor-12	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-12 (compound 34) is a sEH inhibitor with an IC₅₀ value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC₅₀ value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation .

HY-P99459

Baminercept BG 9924; TT-47	TNF Receptor	Inflammation/Immunology
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .

HY-123571

CP-199330	Leukotriene Receptor	Inflammation/Immunology
CP-199330 is a potent and orally active cysteinyl LT1 receptor antagonist .

HY-161709

FLT3/CDKs ligand-1	Ligands for Target Protein for PROTAC FLT3 CDK	Cancer
FLT3/CDKs ligand-1 (Compound 14) is a ligand for target protein, which promotes the degradation of cyclin-dependent kinase (CDK) and the FMS-like tyrosine kinase 3 (FLT3), inhibits FLT3/CDK related proliferations and survivals of leukemia cells. LT3/CDKs ligand-1 can be used for synthesis of PROTAC FLT3/CDKs degrader-1 (HY-161708) .

HY-107609

BAY-u 9773	Leukotriene Receptor	Inflammation/Immunology
BAY-u 9773 is a non-selective antagonist of the CysLT receptors (cysteinyl leukotrienes receptors) with about the same IC₅₀ for CysLT ¹ and CysLT ². BAY-u9773 is used for the inhibition of LT responses .

HY-14687

(rac)-Talazoparib (rac)-BMN-673; (rac)-LT-673	PARP	Cancer
(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for PARP1/2 with K_i of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC₅₀ of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC₅₀ of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models .

HY-151617

sEH inhibitor-11	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-11 (compound 35) is a sEH inhibitor with an IC₅₀ value of 0.3 μM. sEH inhibitor-11 can be used for the research of inflammation .

HY-141467

Propionyl CoA	Others	Metabolic Disease
Propionyl CoA serves as a common intermediate in the catabolic pathways of 1,2-propanediol and propionate in Salmonella enterica serovar Typhimurium LT2, and also functions as a precursor for 2-methylcitrate. Propionyl CoA is utilized as a substrate for the 2-methylcitrate synthase (PrpC) enzyme to synthesize 2-methylcitrate .

HY-N6607

Tryptanthrin 5+ Cited Publications	Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-10037

Quiflapon 1 Publications Verification MK-591	FLAP Apoptosis	Inflammation/Immunology
Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC₅₀ of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active Leukotriene biosynthesis (LT) inhibitor, shows IC₅₀ values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis .

HY-127110

AK106-001616	Phospholipase	Others Neurological Disease Inflammation/Immunology
AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC₅₀=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis .

HY-19042

YM-16638 YM 638	Leukotriene Receptor	Inflammation/Immunology
YM-16638 is an orally active leukotriene (LT) antagonist. YM-16638 can inhibit the production of LTC₄, LTD₄, and LTE₄ in guinea pig trachea, with IC₅₀ values of 0.05 μM, 0.16 μM, and 0.096 μM, respectively. YM-16638 has a dose-dependent inhibitory effect on antigen-induced early and late respiratory responses in allergic sheep .

HY-14162

AM103 free acid	FLAP	Inflammation/Immunology
AM103 (free acid) is a selective FLAP inhibitor that can block the first step of the LT pathway, which is 5-LO activation. AM103 (free acid) can inhibit the production of LTB₄ and cysteinyl leukotrienes (CysLT). AM103 (free acid) has anti-inflammatory activity in a mouse model of chronic lung inflammation and can extend the survival time of mice injected with platelet-activating factor. AM103 (free acid) can be used for research on respiratory diseases such as asthma .

HY-N6607R

Tryptanthrin (Standard)	Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
Tryptanthrin (Standard) is the analytical standard of Tryptanthrin. This product is intended for research and analytical applications. Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-16106A

(8R,9S)-Talazoparib (8R,9S)-BMN-673; (8R,9S)-LT-673	PARP	Cancer
(8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an PARP1 inhibitor, with an IC₅₀ of 144 nM .

HY-10037R

Quiflapon (Standard) MK-591 (Standard)	FLAP Apoptosis	Inflammation/Immunology
Quiflapon (Standard) is the analytical standard of Quiflapon. This product is intended for research and analytical applications. Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50?of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active?Leukotriene biosynthesis (LT)?inhibitor, shows IC50?values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis .

HY-155408

ALR-27	FLAP	Inflammation/Immunology
ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes .

HY-124801

ABMA 1 Publications Verification	Flavivirus Dengue Virus Bacterial Parasite	Infection
ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activity .

HY-159922

AR antagonist 9	Androgen Receptor	Cancer
AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC₅₀ value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC₅₀ = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against *AR_F876L/T877A* and AR_W741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .

HY-117947

(R)-OR-S1	Histone Methyltransferase	Cancer
(R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.

Cat. No.	Product Name	Target	Research Area

HY-P99318

Sonepcizumab LT 1009; Anti-Human S1P Recombinant Antibody	LPL Receptor	Cancer
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .

HY-P99459

Baminercept BG 9924; TT-47	TNF Receptor	Inflammation/Immunology
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .

HY-P990034

Pateclizumab MLTA3698A; RG7415; PRO283698	Inhibitory Antibodies	Inflammation/Immunology
Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6607

Tryptanthrin 5+ Cited Publications	Alkaloids Structural Classification Classification of Application Fields Polygonaceae Source classification Plants Polygonum tinctorium Ait. Inflammation/Immunology Disease Research Fields Indole Alkaloids	Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related
Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-N6607R

Tryptanthrin (Standard)	Alkaloids Structural Classification Polygonaceae Source classification Plants Polygonum tinctorium Ait. Indole Alkaloids	Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related
Tryptanthrin (Standard) is the analytical standard of Tryptanthrin. This product is intended for research and analytical applications. Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

Species:	Human (6) Mouse (1) Cynomolgus (1)
Tag:	His (6) Tag Free (1) Avi (1) GST (1) Flag (1)
Source:	HEK293 (2) Sf9 insect cells (3) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P7304

	TNF-beta/TNFSF1 Protein, Human rHuTNF-β; TNF-β; TNFSF1; Lymphotoxin-alpha	Human	E. coli
	TNF-β (tumor necrosis factor β) also called lymphotoxin-α (LT-α), a member of the tumor necrosis factor superfamily, is a cytokine produced by lymphocytes. TNF-β activates the NF-κB signaling pathway, inducing cancer cell proliferation, invasion. TNF-β up-regulates genes connected with metastasis, promotes epithelial-to-mesenchymal-transition, stimulates its own expression. TNF-β mediates a large variety of inflammatory, immunostimulatory, and antiviral responses. TNF-beta/TNFSF1 Protein, Human is a recombinant protein consisting of 158 amino acids (L35-L205) and is produced in E. coli.

HY-P700419

	TNF-beta/TNFSF1 Protein, Human (HEK293, His) LTA; lymphotoxin alpha (TNF superfamily, member 1); LT; TNFB; TNFSF1; lymphotoxin alpha; OTTHUMP00000165897; tumor necrosis factor beta; Tumor necrosis factor ligand superfamily member 1; TNF-beta; LT-alpha	Human	HEK293
	TNF-β protein acts as a homotrimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM. TNF-beta/TNFSF1 Protein, Human (HEK293, His) is the recombinant human-derived TNF-beta/TNFSF1 protein, expressed by HEK293 , with N-6*His labeled tag.

HY-P700154AF

	Animal-Free TNF-beta/TNFSF1 Protein, Human (His) Lymphotoxin-Alpha; LT-Alpha; TNF-beta; Tumor Necrosis Factor Ligand Superfamily Member 1; LTA; TNFB; TNFSF1	Human	E. coli
	TNF-β protein acts as a homotrimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM. Animal-Free TNF-beta/TNFSF1 Protein, Human (His) is the recombinant human-derived animal-FreeTNF-beta/TNFSF1 protein, expressed by E. coli , with N-His labeled tag. This product is for cell culture use only.

HY-P700228AF

	Animal-Free TNF beta Protein, Mouse (His) TNFSF1B; Lymphotoxin-alpha (LT-α); LTalpha; LTx; TNF-be; TNFSF1; Tnf; Tnfb; Tnfsf; Tnfsf1b; Tnlg1e; hlb38; hlb382; lymph	Mouse	E. coli
	The animal-free TNF beta protein acts as a homotrimeric cytokine that binds TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM.Animal-Free TNF beta Protein, Mouse (His) is the recombinant mouse-derived animal-FreeTNF beta protein, expressed by E.coli , with N-His labeled tag.This product is for cell culture use only.

HY-P703107

	LT4R1 Protein, Human (Sf9, Flag, His) BLT; BLT1; BLTR; CMKRL1; GPR16; P2RY7	Human	Sf9 insect cells
	LT4R1 Protein, Human (Sf9, Flag, His) is the recombinant human-derived LT4R1, expressed by Sf9 insect cells , with His, Flag labeled tag. ,

HY-P700612

	TNF-beta/TNFSF1 Protein, Human (HEK293, His-Avi) LTA; lymphotoxin alpha (TNF superfamily, member 1); LT; TNFB; TNFSF1; lymphotoxin alpha; OTTHUMP00000165897; tumor necrosis factor beta; Tumor necrosis factor ligand superfamily member 1; TNF-beta; LT-alpha	Human	HEK293
	TNF-β protein acts as a homotrimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM. TNF-beta/TNFSF1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived TNF-beta/TNFSF1 protein, expressed by HEK293 , with N-Avi, N-6*His labeled tag.

HY-P76482

	TNFSF3/Lymphotoxin Beta Protein, Cynomolgus (sf9, His) Lymphotoxin-beta; LT-beta; Tumor necrosis factor C; TNF-C; LTB; TNFSF3	Cynomolgus	Sf9 insect cells
	Lymphotoxin Beta (LT-beta) also known as TNFSF3, is a type II transmembrane glycoprotein of the TNF family. Lymphotoxin Beta binds to LTα to form membrane-anchored heterotrimers that activate canonical/noncanonical nuclear factor-κB (NF-κB) signaling thus inducing chemokine, cytokine or adhesion molecule expression, cell proliferation and cell survival. Lymphotoxin Beta also shows anti-inflammatory, anti-cancer activity. Lymphotoxin Beta regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. TNFSF3/Lymphotoxin Beta Protein, Cynomolgus (sf9, His) is a recombinant protein with a N-Terminal His label, It consists of 197 amino acids (Q49-G244) and is produced in Sf9 insect cells.

HY-P701740

	PHKG2 Protein, Human (Sf9, GST) PHKG2; Phosphorylase b kinase gamma catalytic chain; liver/testis isoform; PHK-gamma-LT; PHK-gamma-T; PSK-C3; Phosphorylase kinase subunit gamma-2	Human	Sf9 insect cells
	As the catalytic subunit of phosphorylase b kinase (PHK), PHKG2 plays a crucial role in the neural and hormonal regulation of glycogenolysis (glycogen breakdown) by phosphorylating and activating glycogen phosphorylase. Furthermore, PHKG2 has a potential role in regulating testicular glycogenolysis. PHKG2 Protein, Human (Sf9, GST) is the recombinant human-derived PHKG2 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-16106S1

Talazoparib-d4
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83511

	SV40 T Antigen Antibody (YA3256) Large T antigen; LT; LT-AG	WB, ICC/IF, IP	Species independent
	SV40 T Antigen Antibody (YA3256) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3256), targeting SV40 T Antigen, with a predicted molecular weight of 82 kDa (observed band size: 90 kDa). SV40 T Antigen Antibody (YA3256) can be used for WB, ICC/IF, IP experiment in species independent background.

HY-P83589

	Lymphotoxin alpha Antibody (YA3334) LTalpha; DIF; LT alpha; LTa; Lymphotoxin alpha; TNF B; TNF superfamily member 1; TNF-beta; TNFB; TNFbeta; TNFSF1; TNLG1E	WB	Human
	Lymphotoxin alpha Antibody (YA3334) is a non-conjugated IgG antibody, targeting Lymphotoxin alpha, with a predicted molecular weight of 22 kDa (observed band size: 18 kDa). Lymphotoxin alpha Antibody (YA3334) can be used for WB experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks